Cellectis

Cellectis is a gene-editing company employing its core proprietary technologies to develop products in the field of immuno-oncology. UCART19 is Co.'s lead product. UCART19 is an engineered T-cell product which drives its ability to target and kill CD19-bearing cells, such as B-cell malignancies. Co. is also developing wholly-owned product candidates UCART123, UCARTCS1 and UCART38, which are in various stages of development. UCART 123, UCARTCS1 and UCART38 are engineered T-cell products that bear CARs that seek to kill cells expressing targets CD123, CS1 and CD38, respectively, which are found in other hematologic tumors, such as acute myeloid leukemia, or AML, and multiple myeloma, or MM.
  • TickerALCLS
  • ISINFR0010425595
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Gary Waanders

CELLECTIS: Cellectis Q1 operational and financial update | NEUTRAL | EUR21 (+19%)

CELLECTIS - NEUTRAL | EUR21 (+19%) Cellectis Q1 operational and financial update Q1 focus on broadening pipeline and manufacturing Proprietary pipeline growing In-house manufacturing facilities – self determination Competitive position

Martial Descoutures ...
  • Pierre Corby

Cellectis : A year of phase I trials

>Cash burn well negotiated but set to accelerate - Yesterday, the French biotech reported its financial results followed by a conference call. With a cash position of $ 452m at end-2018, the group has excellent financial visibility although this has been reduced to 2021 (vs 2022 initially). Our forecast stood well below this position with a previous estimate of only € 380m. R&D and SG&A charges were broadly stable at between 2017 and 2018. Notably due to the posi...

Martial Descoutures ...
  • Pierre Corby

Cellectis : Une année de phases 1

>Une consommation de trésorerie bien négociée mais qui devrait s’accroître - La biotech française publiait hier ses résultats financiers suivis d’une conférence téléphonique. Avec 452 M$ de trésorerie fin 2018, le groupe a une excellente visibilité financière bien qu’elle se soit réduite à 2021 (vs 2022 initialement). Nous étions nettement en dessous de cette position enregistrant préalablement seulement 380 M€. Les frais de R&D et de SG&A ressortent globalement ...

Martial Descoutures ...
  • Pierre Corby

Cellectis : Phase II trial for UCART19 should be launched in 2020

>A solid partnership - Allogene, the US partner of Cellectis, published its Q4 2018 results on Friday afternoon. With a cash position of $ 721m, the company has excellent visibility on its finances (cash burn of just over $ 200m per year). It was, above all, an opportunity for an update from the US biotech regarding the clinical progress in its product portfolio. Bear in mind that Cellectis has an agreement with Allogene about a group of candidate drugs, the best...

Martial Descoutures ...
  • Pierre Corby

Cellectis : La phase 2 d’UCART19 devrait être lancée en 2020

>Un partenariat solide - Allogene, partenaire US de Cellectis, publiait vendredi dernier après midi ses résultats du T4 2018. Avec 721 M$ de trésorerie, la société a une excellente visibilité financière (cash burn d’un peu plus de 200 M$ par an). C’était surtout l’occasion pour la biotech américaine de refaire un point sur les avancées cliniques de son portefeuille produits. Pour rappel, Cellectis a un accord avec Allogene sur un ensemble de candidats médicaments...

A director sold 10,000 shares at 22.500EUR and

A director at Cellectis sold 10,000 shares at 22.500EUR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

Charles Lepetitpas ...
  • Christophe Chaput
  • Emmanuel Matot
  • Geoffroy Michalet
  • Jean Sassus
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Martial Descoutures
  • Nicolas Thorez
  • Nicolas David
  • Oussema Denguir
  • Pierre Corby
  • Steven Gould

ODDO BHF Small & MIDCAP MORNING NEWS - 03/13/2019

Offshore and FPSO-type floating production systems will remain key for the future balance of the oil market. Between now and 2035, new offshore projects producing an additional 20 mb/d will have to be launched! We expect an acceleration in momentum in this segment after several years of underinvestment. SBM Offshore, on which we adopt a Buy recommendation (vs Neutral) with a target price of € 22, is the key player in this segment in our view. We remain more cautious on players with a ...

Charles Lepetitpas ...
  • Christophe Chaput
  • Emmanuel Matot
  • Geoffroy Michalet
  • Jean Sassus
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Martial Descoutures
  • Nicolas Thorez
  • Nicolas David
  • Oussema Denguir
  • Pierre Corby
  • Steven Gould

ODDO BHF Small & MIDCAP MORNING NEWS - 13/03/2019

...

Benoit Valleaux ...
  • Martial Descoutures
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 03/11/2019

...

Benoit Valleaux ...
  • Martial Descoutures
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 11/03/2019

...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

MarketLine Department

Bellicum Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Bellicum Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Bellicum Pharmaceuticals, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its c...

Charles Pinel

Cellectis 25 juin 2019

Comme lors de l'exercice précédent, Proxinvest regrette que la société maintienne la possibilité de l'usage des autorisations d'augmentation du capital en période d'offre publique, ce qui nous conduit à recommander l'opposition aux résolutions 10 à 12, 14 et 15. Par ailleurs, les montants proposés dans ces résolutions ainsi que dans les résolutions 19 à 23 sont excessifs. Proxinvest regrette également le manque de communication concernant les rémunérations des dirigeants. De plus, la société empêche les actionnaires de se prononcer sur la rémunération en ne soumettant pas au vote de résolutio...

Jehanne Leroy

Etude de l'AG du 26/06/2017

Cette année encore, la société se distingue par le manque de transparence dans sa communication. En effet, au jour de rédaction de cette étude (14 jours avant l'Assemblée Générale), la société n'a pas transmis l'ensemble des documents nécéssaires à la prise de décision éclairée des actionnaires. Ce manque de transparence conduit Proxinvest à recommander aux actionnaires de s'opposer à une très grande majorité des résolutions proposées lors de l'Assemblée Générale. Proxinvest regrette par ailleurs que la société maintienne la possibilité de l'usage de ces autorisations financières en période ...

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

Valérie GASTALDY

Short term view - CELLECTIS : The background trend is clearly bullish.

The background trend is clearly bullish. Prices are still making progress. The following targets are at €26.88 and €29.80. The trend would be invalidated below the support at €18.32.

Valérie GASTALDY

Analyse court terme - CELLECTIS : La tendance de fond est clairement orientée à la hausse.

La tendance de fond est clairement orientée à la hausse. Les cours progressent toujours. Les objectifs suivants sont à 26,88 € et 29,80 €. La tendance serait invalidée sous le support à 18,32 €.

Louis AZAIS

Analyse moyen terme - CELLECTIS : Les cours progressent toujours.

La tendance de fond est clairement orientée à la hausse. Les cours progressent toujours. Les objectifs suivants sont à 30,00 € et 41,77 €. La tendance serait invalidée sous le support à 14,60 €.

Louis AZAIS

Medium term view - CELLECTIS : Prices are still making progress.

The background trend is clearly bullish. Prices are still making progress. The following targets are at €30.00 and €41.77. The trend would be invalidated below the support at €14.60.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch